EGFR mutation + ANKRD1 overexpression	Non Small Cell Lung Cancer	EGFR mutation + ANKRD1 overexpression	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + ANKRD1 overexpression	Lung Adenocarcinoma	EGFR mutation + ANKRD1 overexpression	Lung Adenocarcinoma	afatinib Resistant: D – Preclinical afatinib Resistant : D	afatinib Resistant: D – Preclinical afatinib Resistant : D
EGFR mutation + ANKRD1 overexpression	Lung Adenocarcinoma	EGFR mutation + ANKRD1 overexpression	Lung Adenocarcinoma	osimertinib Resistant: D – Preclinical osimertinib Resistant : D	osimertinib Resistant: D – Preclinical osimertinib Resistant : D

EGFR mutation + ANKRD1 overexpression

Associations